E2007 (perampanel) + Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Neuralgia
Conditions
Neuralgia
Trial Timeline
Jan 1, 2008 → Mar 1, 2009
NCT ID
NCT00592774About E2007 (perampanel) + Placebo
E2007 (perampanel) + Placebo is a phase 2 stage product being developed by Eisai for Neuralgia. The current trial status is completed. This product is registered under clinical trial identifier NCT00592774. Target conditions include Neuralgia.
What happened to similar drugs?
8 of 18 similar drugs in Neuralgia were approved
Approved (8) Terminated (3) Active (8)
🔄Placebo + Pregabalin SR tablet 165mg/day + Pregabalin SR tablet 330mg/day + Pregabalin SR tablet 660mg/dayJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00592774 | Phase 2 | Completed |
| NCT00144690 | Phase 2 | Completed |
Competing Products
20 competing products in Neuralgia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Placebo + DS-5565 | Daiichi Sankyo | Pre-clinical | 26 |
| QUTENZA | Astellas Pharma | Approved | 43 |
| ASP8477 + Placebo | Astellas Pharma | Phase 2 | 35 |
| E2007 | Eisai | Phase 2/3 | 38 |
| KHK6188 + Placebo | Kyowa Kirin | Phase 2 | 35 |
| ONO-1110 + Placebo | Ono Pharmaceutical | Phase 2 | 39 |
| Galcanezumab | Eli Lilly | Approved | 43 |
| Placebo + Pregabalin SR tablet 165mg/day + Pregabalin SR tablet 330mg/day + Pregabalin SR tablet 660mg/day | Jiangsu Hengrui Medicine | Phase 3 | 36 |
| ABT-894 + ABT-894 + ABT-894 + placebo + Duloxetine | AbbVie | Phase 2 | 35 |
| MK-8291 + Placebo | Merck | Phase 1 | 29 |
| Etoricoxib + Placebo | Merck | Approved | 39 |
| Cetuximab + Placebo | Merck | Phase 2 | 35 |
| ADL5747 + Placebo + Pregabalin | Merck | Phase 2 | 27 |
| MK0759 | Merck | Phase 2 | 27 |
| MK0686 | Merck | Phase 2 | 27 |
| Comparator: pregabalin + Comparator: Placebo (unspecified) | Merck | Phase 1 | 29 |
| EMA401 + Placebo | Novartis | Phase 2 | 27 |
| pregabalin | Pfizer | Approved | 43 |
| Lyrica (pregabalin) + Placebo | Pfizer | Approved | 43 |
| 2-weeks placebo then gabapentin + 1-week placebo then gabapentin | Pfizer | Pre-clinical | 26 |